Hisamitsu Announces U.S. Launch of its "Fentanyl Transdermal System" for the Management of Chronic Pain

The Company's Official Page[PDF]
http://www.hisamitsu.co.jp/english/pdf/HFG_E_100325.pdf
Back To Previous Page


March 25, 2010
Hisamitsu Announces U.S. Launch of its “Fentanyl Transdermal System” for
the Management of Chronic Pain
Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President:
Hirotaka Nakatomi; hereinafter “Hisamitsu Pharmaceutical”) announces that on March 24, 2010 (local time in U.S.) Apotex Corp. (Head Office: Florida, U.S.; Chief Commercial Officer:Jeff Watson; hereinafter “Apotex”) launched Hisamitsu Pharmaceutical’s “Fentanyl Transdermal System” for the management of chronic pain, which was approved by the U.S. Food and

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Notice Regarding Worldwide Patent and Kn...
Mitsubishi Tanabe Pharma Corporation 2015/09/17
2. Announcement of FY2015 2nd Quarter Finan...
Mitsubishi Tanabe Pharma Corporation 2015/10/30
3. Mitsubishi Tanabe Pharma Enhances Operat...
Mitsubishi Tanabe Pharma Corporation 2016/02/23
4. Notice of Dividend of Retained Earnings
Mitsubishi Tanabe Pharma Corporation 2016/05/11
5. Approval of REMICADE for I.V. Infusion 1...
Mitsubishi Tanabe Pharma Corporation 2016/05/13

Latest News: Hisamitsu Pharmaceutical Co., Inc.


Most Popular: Hisamitsu Pharmaceutical Co., Inc.

1. Notice concerning acquisition result and...
2009/12/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us